Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases

The aim of this study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of R0 excision Colorectal Cancer Liver Metastases.

Trial Details

NCT ID

NCT06545630

Phase

PHASE1

Sponsor

West China Hospital

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

Tumor antigen-sensitized DC vaccine

Locations (sample)

Chengdu, Chengdu/Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

Pathologically confirmed diagnosis of colorectal cancer； Karnofsky performance status 0-1; Patients with tumors identified by pathologic immunohist…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →